The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: Comparison with standard subcutaneous octreotide therapy

By Dogliotti L.   Tampellini M.   Stivanello M.   Gorzegno G.   Fabiani L.  

Annals of Oncology, Vol. 12, Iss. 2, 2001-02 ,pp. : 105-109

Springer Publishing Company

Access to resources Recommend Favorite

Treatment with High Dose [¹¹¹In-DTPA-D-PHE¹]-Octreotide in Patients with Neuroendocrine Tumors: Evaluation of Therapeutic and Toxic Effects

By Janson Eva Tiensuu   Eriksson Barbro   Öberg Kjell   Skogseid Britt   Öhrvall Ulf   Nilsson Sten   Westlin Jan-Erik  

Acta Oncologica, Vol. 38, Iss. 3, 1999-05 ,pp. : 373-377

Informa Healthcare

Access to resources Recommend Favorite

Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies

By Rosenoff Stephen  

Supportive Care in Cancer, Vol. 12, Iss. 8, 2004-08 ,pp. : 561-570

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors

By Masters Gregory   Brockstein Bruce   Mani Sridhar   Ratain Mark  

Medical Oncology, Vol. 20, Iss. 1, 2003-03 ,pp. : 7-12

Humana Press, Inc

Access to resources Recommend Favorite

A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-α2b in patients with solid tumors

By Schneider Bryan   Fukunaga Anna   Murry Daryl   Yoder Christy   Fife Karen   Foster Anne   Rosenberg Leslie   Kelich Stephanie   Li Lang   Sweeney Christopher  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 2, 2007-02 ,pp. : 261-268

Springer Publishing Company

Access to resources Recommend Favorite